Kalaris Therapeutics, Inc. fell 18.7% on Tuesday, November 10, 2026, on 81,400 shares. The headline around the move:
Kalaris Therapeutics, Inc. (KLRS:NASDAQ) closed at $1.58 on November 13, 2026, down 5.12% on the day. The stock trades 86.7% below its 52-week high of $11.88 and 1.6% above its 52-week low of $1.55. Over the past year, it lost 70.9%. Kalaris Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, KLRS closed higher on 104 days (41%). Its best day was February 18, 2026 (+23.90%) and its worst was November 10, 2026 (-18.70%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 1 time.
Kalaris was founded by experienced leaders in ophthalmology drug development and commercialization to address a major unmet need in the treatment of retinal diseases.Existing therapies for retinal neovascular / exudative diseases have made great strides in preserving or improving vision, but they require frequent clinic visits over many years that place a significant burden on patients and caregivers. This onerous visit regimen often leads to missed or delayed injections and suboptimal patient outcomes.
Find more stocks like KLRS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.